Indication name: Cryptococcosis
"Cryptococcosis – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020
To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy,
Japan & China)
Cryptococcosis also known as
Busse-Buschke Disease, Cryptococcic Meningitis, Cryptococcosis Lung,
Cryptococcosis Skin, European Blastomycosis and Torular Meningitis
Cryptococcosis is an infectious
disease with worldwide distribution and wide array of clinical presentations
caused by pathogenic encapsulated yeasts in the genus Cryptococcus. It caused
by a fungus known as Cryptococcosis neoformans and C. gattii . It is spread by
contact with pigeon droppings, unwashed raw fruit or by infected individuals.
According to Thelansis C.
neoformans infections are rare among people who have healthy immune systems;
however, C. neoformans is a major cause of illness in people living with HIV/AIDS,
with an estimated 220,000 cases of cryptococcal meningitis occurring worldwide
each year.
Competitive landscape of
Cryptococcosis includes country specific approved as well as pipeline
therapies. Any asset/ product specific designation or review and Accelerated
Approval are being tracked and supplemented with analyst commentary.
KOLs
insights of Cryptococcosis across 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Cryptococcosis Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden and pricing scenario, Summary and Insights.
MAT2203- Matinas BioPharma
AK1820 - Asahi Kasei Pharma
Corporation
No comments:
Post a Comment